Global Therapeutic Vaccines Market is expected to reach US$ 134.6 Bn. at a CAGR of 26.63 % during the forecast period 2029. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global market dynamics, structure by identifying and analysing the market segments and project the global market size.To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global market. Global therapeutic vaccines market is fixed to witness great growth opportunities in recent times. This can be attributed to the increasing awareness of communicable diseases and new threats, cost-effectiveness of vaccines, development in new research techniques and growing demand, new target population and the emergence of developing markets. The major driving factor such as the increasing occurrence of cancer, cardiovascular diseases, HIV infection and several chronic diseases are boosting the market. In addition, Increase in funding’s from the government for vaccine development and growing awareness among people for severe disease are the key factors escalating the growth of global therapeutic vaccines market. With the increasing demand for different types of vaccines to be introduced into the market, there is one restraint to this situation. The vaccine research requires huge capital to be invested and a lot of time to be spent. Autoimmune disease vaccine segment is expected to grow at the fastest rate in the global market over the forecast period. The autoimmune is the system of immune responses of an organism against its own healthy cells and tissues. Some disease that results from such an aberrant immune response is termed an "autoimmune disease vaccine". Region-wise, North America represents developed regional markets for therapeutic vaccines and is anticipated to see the rapid growth in the upcoming years. The US is by far the leading therapeutic vaccine market by country in North America. The US market is predictable to grow at the highest CAGR during the forecast period. This growth is mainly owing to the well-developed healthcare infrastructure and increases in research and development on a therapeutic vaccine. Additionally, the disposable income and reimbursement of life-threatening diseases are very high in this region which promotes the growth of global therapeutic vaccine market. Europe was the second largest regional market and is estimated to show significant growth in the years to come. This growth is mainly as of increase in a number of patients diagnosed with cancer.
Scope Global Therapeutic Vaccines Market: Inquire before buying
Global Therapeutic Vaccines Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 25.78 Bn. Forecast Period 2023 to 2029 CAGR: 26.63% Market Size in 2029: US $ 134.6 Bn. Segments Covered: by Product Addiction Vaccines Autoimmune Disease Vaccines Infectious Disease Vaccines Neurological Disease Vaccines by Technology Autologous vaccines Allogeneic vaccines Global Market, by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key players operating in Global Therapeutic Vaccines Market
1. Sanofi-Pasteur 2. Cytos Biotechnology AG 3. Intellect Neurosciences 4. Agenus Inc. 5. Celtic Pharma, 6. Novartis 7. Dendreon Corp. 8. Pfizer 9. Transgene 10. Antigenics 11. Argos Therapeutics 12. Bavarian Nordic 13. Biovest International 14. Celldex Therapeutics 15. Cel-Sci 16. Curevac 17. GlaxoSmithKline 18. Merck & Co. 19. Vaccinogen Inc. 20. Affiris 21. Medimmune, LLC Frequently Asked Questions: 1. Which region has the largest share in Global Therapeutic Vaccines Market? Ans: Asia Pacific region holds the highest share in 2022. 2. What is the growth rate of Global Therapeutic Vaccines Market? Ans: The Global Therapeutic Vaccines Market is growing at a CAGR of 26.63% during forecasting period 2023-2029. 3. What is scope of the Global Therapeutic Vaccines Market report? Ans: Global Therapeutic Vaccines Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. What is the study period of this market? Ans: The Global Therapeutic Vaccines Market is studied from 2022 to 2029.
Global Therapeutic Vaccines Market
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Therapeutic Vaccines Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Therapeutic Vaccines Market Analysis and Forecast 6.1. Global Therapeutic Vaccines Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Therapeutic Vaccines Market Analysis and Forecast, by Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Therapeutic Vaccines Market Value Share Analysis, by Product 7.4. Global Therapeutic Vaccines Market Size (US$ Bn) Forecast, by Product 7.5. Global Therapeutic Vaccines Market Analysis, by Product 7.6. Global Therapeutic Vaccines Market Attractiveness Analysis, by Product 8. Global Therapeutic Vaccines Market Analysis and Forecast, by Technology 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Therapeutic Vaccines Market Value Share Analysis, by Technology 8.4. Global Therapeutic Vaccines Market Size (US$ Bn) Forecast, by Technology 8.5. Global Therapeutic Vaccines Market Analysis, by Technology 8.6. Global Therapeutic Vaccines Market Attractiveness Analysis, by Technology 9. Global Therapeutic Vaccines Market Analysis, by Region 9.1. Global Therapeutic Vaccines Market Value Share Analysis, by Region 9.2. Global Therapeutic Vaccines Market Size (US$ Bn) Forecast, by Region 9.3. Global Therapeutic Vaccines Market Attractiveness Analysis, by Region 10. North America Therapeutic Vaccines Market Analysis 10.1. Key Findings 10.2. North America Therapeutic Vaccines Market Overview 10.3. North America Therapeutic Vaccines Market Value Share Analysis, by Product 10.4. North America Therapeutic Vaccines Market Forecast, by Product 10.4.1. Addiction Vaccines 10.4.2. Autoimmune Disease Vaccines 10.4.3. Infectious Disease Vaccines 10.4.4. Neurological Disease Vaccines 10.5. North America Therapeutic Vaccines Market Value Share Analysis, by Technology 10.6. North America Therapeutic Vaccines Market Forecast, by Technology 10.6.1. Autologous vaccines 10.6.2. Allogeneic vaccines 10.7. North America Therapeutic Vaccines Market Value Share Analysis, by Country 10.8. North America Therapeutic Vaccines Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Therapeutic Vaccines Market Analysis, by Country 10.10. U.S. Therapeutic Vaccines Market Forecast, by Product 10.10.1. Addiction Vaccines 10.10.2. Autoimmune Disease Vaccines 10.10.3. Infectious Disease Vaccines 10.10.4. Neurological Disease Vaccines 10.11. U.S. Therapeutic Vaccines Market Forecast, by Technology 10.11.1. Autologous vaccines 10.11.2. Allogeneic vaccines 10.12. Canada Therapeutic Vaccines Market Forecast, by Product 10.12.1. Addiction Vaccines 10.12.2. Autoimmune Disease Vaccines 10.12.3. Infectious Disease Vaccines 10.12.4. Neurological Disease Vaccines 10.13. Canada Therapeutic Vaccines Market Forecast, by Technology 10.13.1. Autologous vaccines 10.13.2. Allogeneic vaccines 10.14. North America Therapeutic Vaccines Market Attractiveness Analysis 10.14.1. By Product 10.14.2. By Technology 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Therapeutic Vaccines Market Analysis 11.1. Key Findings 11.2. Europe Therapeutic Vaccines Market Overview 11.3. Europe Therapeutic Vaccines Market Value Share Analysis, by Product 11.4. Europe Therapeutic Vaccines Market Forecast, by Product 11.4.1. Addiction Vaccines 11.4.2. Autoimmune Disease Vaccines 11.4.3. Infectious Disease Vaccines 11.4.4. Neurological Disease Vaccines 11.5. Europe Therapeutic Vaccines Market Value Share Analysis, by Technology 11.6. Europe Therapeutic Vaccines Market Forecast, by Technology 11.6.1. Autologous vaccines 11.6.2. Allogeneic vaccines 11.7. Europe Therapeutic Vaccines Market Value Share Analysis, by Country 11.8. Europe Therapeutic Vaccines Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Therapeutic Vaccines Market Analysis, by Country 11.10. Germany Therapeutic Vaccines Market Forecast, by Product 11.10.1. Addiction Vaccines 11.10.2. Autoimmune Disease Vaccines 11.10.3. Infectious Disease Vaccines 11.10.4. Neurological Disease Vaccines 11.11. Germany Therapeutic Vaccines Market Forecast, by Technology 11.11.1. Autologous vaccines 11.11.2. Allogeneic vaccines 11.12. U.K. Therapeutic Vaccines Market Forecast, by Product 11.12.1. Addiction Vaccines 11.12.2. Autoimmune Disease Vaccines 11.12.3. Infectious Disease Vaccines 11.12.4. Neurological Disease Vaccines 11.13. U.K. Therapeutic Vaccines Market Forecast, by Technology 11.13.1. Autologous vaccines 11.13.2. Allogeneic vaccines 11.14. France Therapeutic Vaccines Market Forecast, by Product 11.14.1. Addiction Vaccines 11.14.2. Autoimmune Disease Vaccines 11.14.3. Infectious Disease Vaccines 11.14.4. Neurological Disease Vaccines 11.15. France Therapeutic Vaccines Market Forecast, by Technology 11.15.1. Autologous vaccines 11.15.2. Allogeneic vaccines 11.16. Italy Therapeutic Vaccines Market Forecast, by Product 11.16.1. Addiction Vaccines 11.16.2. Autoimmune Disease Vaccines 11.16.3. Infectious Disease Vaccines 11.16.4. Neurological Disease Vaccines 11.17. Italy Therapeutic Vaccines Market Forecast, by Technology 11.17.1. Autologous vaccines 11.17.2. Allogeneic vaccines 11.18. Spain Therapeutic Vaccines Market Forecast, by Product 11.18.1. Addiction Vaccines 11.18.2. Autoimmune Disease Vaccines 11.18.3. Infectious Disease Vaccines 11.18.4. Neurological Disease Vaccines 11.19. Spain Therapeutic Vaccines Market Forecast, by Technology 11.19.1. Autologous vaccines 11.19.2. Allogeneic vaccines 11.20. Rest of Europe Therapeutic Vaccines Market Forecast, by Product 11.20.1. Addiction Vaccines 11.20.2. Autoimmune Disease Vaccines 11.20.3. Infectious Disease Vaccines 11.20.4. Neurological Disease Vaccines 11.21. Rest Of Europe Therapeutic Vaccines Market Forecast, by Technology 11.21.1. Autologous vaccines 11.21.2. Allogeneic vaccines 11.22. Europe Therapeutic Vaccines Market Attractiveness Analysis 11.22.1. By Product 11.22.2. By Technology 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Therapeutic Vaccines Market Analysis 12.1. Key Findings 12.2. Asia Pacific Therapeutic Vaccines Market Overview 12.3. Asia Pacific Therapeutic Vaccines Market Value Share Analysis, by Product 12.4. Asia Pacific Therapeutic Vaccines Market Forecast, by Product 12.4.1. Addiction Vaccines 12.4.2. Autoimmune Disease Vaccines 12.4.3. Infectious Disease Vaccines 12.4.4. Neurological Disease Vaccines 12.5. Asia Pacific Therapeutic Vaccines Market Value Share Analysis, by Technology 12.6. Asia Pacific Therapeutic Vaccines Market Forecast, by Technology 12.6.1. Autologous vaccines 12.6.2. Allogeneic vaccines 12.7. Asia Pacific Therapeutic Vaccines Market Value Share Analysis, by Country 12.8. Asia Pacific Therapeutic Vaccines Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Therapeutic Vaccines Market Analysis, by Country 12.10. China Therapeutic Vaccines Market Forecast, by Product 12.10.1. Addiction Vaccines 12.10.2. Autoimmune Disease Vaccines 12.10.3. Infectious Disease Vaccines 12.10.4. Neurological Disease Vaccines 12.11. China Therapeutic Vaccines Market Forecast, by Technology 12.11.1. Autologous vaccines 12.11.2. Allogeneic vaccines 12.12. India Therapeutic Vaccines Market Forecast, by Product 12.12.1. Addiction Vaccines 12.12.2. Autoimmune Disease Vaccines 12.12.3. Infectious Disease Vaccines 12.12.4. Neurological Disease Vaccines 12.13. India Therapeutic Vaccines Market Forecast, by Technology 12.13.1. Autologous vaccines 12.13.2. Allogeneic vaccines 12.14. Japan Therapeutic Vaccines Market Forecast, by Product 12.14.1. Addiction Vaccines 12.14.2. Autoimmune Disease Vaccines 12.14.3. Infectious Disease Vaccines 12.14.4. Neurological Disease Vaccines 12.15. Japan Therapeutic Vaccines Market Forecast, by Technology 12.15.1. Autologous vaccines 12.15.2. Allogeneic vaccines 12.16. ASEAN Therapeutic Vaccines Market Forecast, by Product 12.16.1. Addiction Vaccines 12.16.2. Autoimmune Disease Vaccines 12.16.3. Infectious Disease Vaccines 12.16.4. Neurological Disease Vaccines 12.17. ASEAN Therapeutic Vaccines Market Forecast, by Technology 12.17.1. Autologous vaccines 12.17.2. Allogeneic vaccines 12.18. Rest of Asia Pacific Therapeutic Vaccines Market Forecast, by Product 12.18.1. Addiction Vaccines 12.18.2. Autoimmune Disease Vaccines 12.18.3. Infectious Disease Vaccines 12.18.4. Neurological Disease Vaccines 12.19. Rest of Asia Pacific Therapeutic Vaccines Market Forecast, by Technology 12.19.1. Autologous vaccines 12.19.2. Allogeneic vaccines 12.20. Asia Pacific Therapeutic Vaccines Market Attractiveness Analysis 12.20.1. By Product 12.20.2. By Technology 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Therapeutic Vaccines Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Therapeutic Vaccines Market Overview 13.3. Middle East & Africa Therapeutic Vaccines Market Value Share Analysis, by Product 13.4. Middle East & Africa Therapeutic Vaccines Market Forecast, by Product 13.4.1. Addiction Vaccines 13.4.2. Autoimmune Disease Vaccines 13.4.3. Infectious Disease Vaccines 13.4.4. Neurological Disease Vaccines 13.5. Middle East & Africa Therapeutic Vaccines Market Value Share Analysis, by Technology 13.6. Middle East & Africa Therapeutic Vaccines Market Forecast, by Technology 13.6.1. Autologous vaccines 13.6.2. Allogeneic vaccines 13.7. Middle East & Africa Therapeutic Vaccines Market Value Share Analysis, by Country 13.8. Middle East & Africa Therapeutic Vaccines Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Therapeutic Vaccines Market Analysis, by Country 13.10. GCC Therapeutic Vaccines Market Forecast, by Product 13.10.1. Addiction Vaccines 13.10.2. Autoimmune Disease Vaccines 13.10.3. Infectious Disease Vaccines 13.10.4. Neurological Disease Vaccines 13.11. GCC Therapeutic Vaccines Market Forecast, by Technology 13.11.1. Autologous vaccines 13.11.2. Allogeneic vaccines 13.12. South Africa Therapeutic Vaccines Market Forecast, by Product 13.12.1. Addiction Vaccines 13.12.2. Autoimmune Disease Vaccines 13.12.3. Infectious Disease Vaccines 13.12.4. Neurological Disease Vaccines 13.13. South Africa Therapeutic Vaccines Market Forecast, by Technology 13.13.1. Autologous vaccines 13.13.2. Allogeneic vaccines 13.14. Rest of Middle East & Africa Therapeutic Vaccines Market Forecast, by Product 13.14.1. Addiction Vaccines 13.14.2. Autoimmune Disease Vaccines 13.14.3. Infectious Disease Vaccines 13.14.4. Neurological Disease Vaccines 13.15. Rest of Middle East & Africa Therapeutic Vaccines Market Forecast, by Technology 13.15.1. Autologous vaccines 13.15.2. Allogeneic vaccines 13.16. Middle East & Africa Therapeutic Vaccines Market Attractiveness Analysis 13.16.1. By Product 13.16.2. By Technology 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Developments 14. South America Therapeutic Vaccines Market Analysis 14.1. Key Findings 14.2. South America Therapeutic Vaccines Market Overview 14.3. South America Therapeutic Vaccines Market Value Share Analysis, by Product 14.4. South America Therapeutic Vaccines Market Forecast, by Product 14.4.1. Addiction Vaccines 14.4.2. Autoimmune Disease Vaccines 14.4.3. Infectious Disease Vaccines 14.4.4. Neurological Disease Vaccines 14.5. South America Therapeutic Vaccines Market Value Share Analysis, by Technology 14.6. South America Therapeutic Vaccines Market Forecast, by Technology 14.6.1. Autologous vaccines 14.6.2. Allogeneic vaccines 14.7. South America Therapeutic Vaccines Market Value Share Analysis, by Country 14.8. South America Therapeutic Vaccines Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Therapeutic Vaccines Market Analysis, by Country 14.10. Brazil Therapeutic Vaccines Market Forecast, by Product 14.10.1. Addiction Vaccines 14.10.2. Autoimmune Disease Vaccines 14.10.3. Infectious Disease Vaccines 14.10.4. Neurological Disease Vaccines 14.11. Brazil Therapeutic Vaccines Market Forecast, by Technology 14.11.1. Autologous vaccines 14.11.2. Allogeneic vaccines 14.12. Mexico Therapeutic Vaccines Market Forecast, by Product 14.12.1. Addiction Vaccines 14.12.2. Autoimmune Disease Vaccines 14.12.3. Infectious Disease Vaccines 14.12.4. Neurological Disease Vaccines 14.13. Mexico Therapeutic Vaccines Market Forecast, by Technology 14.13.1. Autologous vaccines 14.13.2. Allogeneic vaccines 14.14. Rest of South America Therapeutic Vaccines Market Forecast, by Product 14.14.1. Addiction Vaccines 14.14.2. Autoimmune Disease Vaccines 14.14.3. Infectious Disease Vaccines 14.14.4. Neurological Disease Vaccines 14.15. Rest of South America Therapeutic Vaccines Market Forecast, by Technology 14.15.1. Autologous vaccines 14.15.2. Allogeneic vaccines 14.16. South America Therapeutic Vaccines Market Attractiveness Analysis 14.16.1. By Product 14.16.2. By Technology 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Sanofi-Pasteur 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Cytos Biotechnology AG 15.3.3. Intellect Neurosciences 15.3.4. Agenus Inc. 15.3.5. Celtic Pharma, 15.3.6. Novartis 15.3.7. Dendreon Corp. 15.3.8. Pfizer 15.3.9. Transgene 15.3.10. Antigenics 15.3.11. Argos Therapeutics 15.3.12. Bavarian Nordic 15.3.13. Biovest International 15.3.14. Celldex Therapeutics 15.3.15. Cel-Sci 15.3.16. Curevac 15.3.17. GlaxoSmithKline 15.3.18. Merck & Co. 15.3.19. Vaccinogen Inc. 15.3.20. Affiris 15.3.21. Medimmune, LLC 16. Primary Key Insights